Used primarily in research settings for studying thrombin receptor (protease-activated receptor-1, PAR-1) antagonism. It has been investigated for its antiplatelet properties, aiming to prevent arterial thrombosis without significantly increasing bleeding risk. Explored in cardiovascular research for potential use in patients with acute coronary syndromes or those undergoing percutaneous coronary intervention. Its development highlights efforts to create targeted therapies that inhibit pathological clotting while preserving normal hemostasis.